Purpose: To compare the surgical outcomes of two modified Yamane techniques for sutureless scleral fixation of intraocular lenses (IOL): trocar-cannula-based fixation and 26-gauge needle-based fixation. Methods: A retrospective analysis was conducted on patients who underwent modified Yamane scleral IOL fixation between January 2023 and June 2024 with a minimum follow-up of 6 months. The outcomes assessed included best corrected visual acuity (BCVA), spherical equivalent, astigmatism, astigmatism, and postoperative complications. Measurements were taken preoperatively and at 1 day, 1 week, 1 month, and 6 months after surgery. Results: Among 86 eyes included, 44 received trocar-cannula-based fixation (trocar group) and 42 received 26-gauge needle-based fixation (needle group). Both groups showed significant improvements in BCVA and spherical equivalent at 6 months postoperatively (BCVA: p = 0.013, p = 0.001; spherical equivalent: p < 0.001, p = 0.014), with no statistically significant differences between the groups (BCVA: p = 0.139; spherical equivalent: p = 0.595). The trocar group demonstrated significantly greater improvement in astigmatism at both 1 month and 6 months (p = 0.046, p = 0.048), as well as in IOL astigmatism at 6 months (p = 0.049). Complication rates did not significantly differ between the groups. Conclusions Both modified Yamane techniques effectively improved BCVA and spherical equivalent. However, the trocar-cannula-based method yielded superior outcomes in astigmatism correction, suggesting a potential advantage in postoperative refractive stability.

Purpose: This study aimed to evaluate the long-term visual outcomes and macular configurations in patients with epiretinal proliferation (ERP) associated with lamellar hole (LH) or macular hole (MH) who underwent pars plana vitrectomy (ppV) using an ERP-preserving technique. Methods: We conducted a retrospective case series involving 26 patients diagnosed with ERP-associated LH or MH who underwent ppV between January 2013 and December 2023 at Hangil Eye Hospital. Surgical procedures involved a 23-gauge ppV, with ERP tissue preservation and internal limiting membrane peeling. Visual acuity and macular configuration were assessed using slit-lamp biomicroscopy, fundus photography, and spectral-domain optical coherence tomography at multiple follow-up points. Statistical analyses were performed using the Wilcoxon signed-rank test. Results: The mean follow-up duration was 42 months. Best-corrected visual acuity improved significantly over time from preoperative values up to 3 years, except at 2 years, after ppV (p = 0.005 at 3 months, 0.012 at 6 months, 0.008 at 9 months, 0.006 at 1 year, 0.068 at 2 years, and 0.024 at 3 years). Postoperative visual acuity remained significantly better than preoperative levels beyond 3 years (p = 0.013). Successful MH closure was obtained in 96.2% of patients. Ellipsoid zone defects were observed in 23 patients preoperatively; of these, eight (34.8%) showed restoration postoperatively. Conclusions The ERP-preserving technique for ppV in patients with ERP-associated LH or MH results in sustained visual acuity improvement for ≥3 years postoperatively.

Purpose: Intermediate age-related macular degeneration (AMD) is characterized by drusen, alterations in the retinal pigment epithelium, and various features of pigment epithelium detachment (PEDs) without exudation. With the advent of optical coherence tomography angiography (OCTA), non-exudative choroidal neovascularization (CNV) has recently been reported in eyes with intermediate AMD.This study investigated the frequency of subclinical, non-exudative CNV in eyes with intermediate AMD using OCTA. Methods: We retrospectively evaluated the optical coherence tomography (OCT) and OCTA images of 140 eyes (97 patients) with intermediate AMD. PEDs were divided into 4 types based on OCT. En-face OCTA and cross-sectional OCTA were performed to detect the presence of non-exudative CNV in eyes with intermediate AMD. Results: The frequency of subclinical non-exudative CNV was 13.8% (17 eyes) in eyes with intermediate AMD. Drusenoid PEDs accounted for 47% (66 eyes), shallow irregular PEDs for 20% (28 eyes), serous PEDs for 19% (26 eyes), and combined PEDs for 15% (20 eyes). Non-exudative CNV was observed only in eyes with shallow irregular PEDs. The frequency of non-exudative CNV in shallow irregular PEDs was 38.6%. Conclusions Subclinical non-exudative CNV was identified in 13.8% of eyes with intermediate AMD, which does not seem to be low.Therefore, OCTA may be necessary to evaluate patients with intermediate AMD, particularly those with shallow irregular PEDs.

Purpose: To evaluate the effect of intraocular pressure (IOP)-lowering medications on myopic retinoschisis. Methods: The medical records of 33 patients (36 eyes) with myopic retinoschisis associated with pathologic myopia were reviewed retrospectively. The patients were divided into two groups: the study group comprising patients undergoing treatment with anti-glaucoma medications for suspected glaucoma; the control group comprising patients who did not use any IOP lowering medications. The changes in retinoschisis in the two groups were compared using the Spectralis domain optical coherence tomography thickness map protocol. Results: The study group included 18 eyes (17 patients), and the control group included 18 eyes (16 patients). There were no significant differences between the 6-month and 12-month improvement or aggravation rates of the two groups (p = 0.513 and 0.137, respectively). However, after 18 months, the aggravation rate of retinoschisis was significantly lower in the study group (p = 0.003). The improvement / aggravation rate was 58.33% / 16.67% in the study group and 0% / 57.14% in the control group. Conclusions The use of IOP-lowering medications for more than a year may be useful for the management of retinoschisis associated with pathologic myopia.

Purpose: To evaluate the effect of intraocular pressure (IOP)-lowering medications on myopic retinoschisis. Methods: The medical records of 33 patients (36 eyes) with myopic retinoschisis associated with pathologic myopia were reviewed retrospectively. The patients were divided into two groups: the study group comprising patients undergoing treatment with anti-glaucoma medications for suspected glaucoma; the control group comprising patients who did not use any IOP lowering medications. The changes in retinoschisis in the two groups were compared using the Spectralis domain optical coherence tomography thickness map protocol. Results: The study group included 18 eyes (17 patients), and the control group included 18 eyes (16 patients). There were no significant differences between the 6-month and 12-month improvement or aggravation rates of the two groups (p = 0.513 and 0.137, respectively). However, after 18 months, the aggravation rate of retinoschisis was significantly lower in the study group (p = 0.003). The improvement / aggravation rate was 58.33% / 16.67% in the study group and 0% / 57.14% in the control group. Conclusions The use of IOP-lowering medications for more than a year may be useful for the management of retinoschisis associated with pathologic myopia.

PURPOSE: To determine the origin of epiretinal proliferation (EP), a condition that is occasionally observed in lamellar hole and macular hole cases, and EP outcomes after vitrectomy. METHODS: This is a retrospective observational case review of 17 eyes with EP that underwent vitrectomy, EP dissection, and internal limiting membrane peeling between January 2013 and December 2016. Surgical specimens of EP tissue were successfully obtained from 5 cases and they were analyzed after immunohistochemical staining. Postoperative outcomes, including best-corrected visual acuity (BCVA) and macular configuration in spectral domain-optical coherence tomography, were reviewed. RESULTS: Mean BCVA improved from 0.54 ± 0.36 logarithms of the minimum angle of resolution preoperatively to 0.32 ± 0.38 logarithms of the minimum angle of resolution postoperatively (p = 0.002). BCVA improved in 13 eyes and remained unchanged in four eyes. No cases experienced vision decline after surgery. All 17 patients' lamellar hole or macular hole were successfully closed. Despite hole closure, ellipsoid zone defects were not corrected in 11 of the 17 patients. In immunohistochemical analyses, anti-glial fibrillary acidic protein and pan-keratin (AE1/AE3) were positive, but synaptophysin, anti-α-smooth muscle actin, and anti-CD68 were negative. CONCLUSIONS: The epiretinal proliferative membrane seems to originate from Müller cells, not from the vitreous. It is unclear whether retinal pigment epithelia also contribute to EP formation. Gentle handling and preservation of the epiretinal proliferative tissue is crucial for successful surgical outcomes.
Actins ; Humans ; Membranes ; Prognosis ; Retinal Perforations ; Retinaldehyde ; Retrospective Studies ; Synaptophysin ; Visual Acuity ; Vitrectomy

PURPOSE: To discuss the unique morphology and origin of epiretinal proliferation associated with macular hole (EPMH) occasionally observed in full-thickness macular hole (FT-MH) or lamellar hole (LH) and to introduce the perifoveal crown phenomenon encountered when removing this unusual proliferative tissue. METHODS: Sixteen patients showing EPMH in spectral domain-optical coherence tomography were selected from 212 patients diagnosed with MH, LH, FT-MH, impending MH, macular pseudohole, or epiretinal membrane between January 2013 and December 2014. Of the 212 patients included for clinical analysis, 33, 23, 11, 7, and 190 exhibited LH, FT-MH, impending MH, macular pseudohole, and epiretinal membrane, respectively. We reviewed visual acuity, macular morphology, and clinical course. Surgical specimens were analyzed histologically. RESULTS: EPMH presented as an amorphous proliferation starting from the defective inner/outer segment (IS/OS) junction covering the inner macula surface. Among the 16 patients with EPMH, 11 underwent vitrectomy, and all exhibited the intraoperative perifoveal crown phenomenon. EPMH tissue was sampled in three patients, one of whom had more tissue removed than intended and showed delayed recovery in visual acuity. Despite hole closure, IS/OS junction integrity was not successfully restored in four of 11 patients. Five patients were followed-up without surgical intervention. Visual acuity slightly decreased in three patients and did not change in one patient, while the remaining patient was lost during follow-up. Among the three perifoveal crown tissues obtained, two were successfully analyzed histologically. Neither tissue showed positivity to synaptophysin or S-100 protein, but one showed positivity to cytokeratin protein immunohistochemical staining. CONCLUSIONS: EPMH exhibited a distinct but common configuration in spectral domain-optical coherence tomography. An epithelial proliferation origin is plausible based on its configuration and histological analysis. Perifoveal crown phenomenon was observed when removing EPMH during vitrectomy.
Aged ; Epiretinal Membrane/*diagnosis/etiology/surgery ; Female ; Follow-Up Studies ; Fovea Centralis/*diagnostic imaging ; Humans ; Intraoperative Period ; Male ; Middle Aged ; Retinal Perforations/complications/*diagnosis/surgery ; Retrospective Studies ; Tomography, Optical Coherence ; Visual Acuity ; *Vitrectomy

PURPOSE: To develop a novel, simplified method for correcting the ischemic index of nonperfused areas in diabetic retinopathy (DR). METHODS: We performed a retrospective review of 103 eyes with naive DR that underwent ultra-widefield angiography (UWFA) over a year. UWFAs were graded according to the quantity of retinal non-perfusion, and uncorrected ischemic index (UII) and corrected ischemic index (CII) were calculated using a simplified, novel method. RESULTS: The average differences between UII and CII in the non-proliferative DR group and the proliferative DR group were 0.7 +/- 0.9% in the <25% CII group, 3.0 +/- 0.9% in the 25% to 49.9% CII group, and 3.6 +/- 0.6% in the >50% CII group, respectively. A CII >25% was critical for determining DR progression (p < 0.001). CONCLUSIONS: Distortion created by UWFA needs to be corrected because the difference between UII and CII in DR increases with the ischemic index.
Adult ; Aged ; Aged, 80 and over ; Diabetic Retinopathy/*diagnosis/pathology ; Female ; Fluorescein Angiography/*methods ; Humans ; Ischemia/pathology ; Male ; Middle Aged ; Retinal Vein/pathology ; Retrospective Studies ; Sensitivity and Specificity

PURPOSE: To develop a novel, simplified method for correcting the ischemic index of nonperfused areas in diabetic retinopathy (DR). METHODS: We performed a retrospective review of 103 eyes with naive DR that underwent ultra-widefield angiography (UWFA) over a year. UWFAs were graded according to the quantity of retinal non-perfusion, and uncorrected ischemic index (UII) and corrected ischemic index (CII) were calculated using a simplified, novel method. RESULTS: The average differences between UII and CII in the non-proliferative DR group and the proliferative DR group were 0.7 +/- 0.9% in the <25% CII group, 3.0 +/- 0.9% in the 25% to 49.9% CII group, and 3.6 +/- 0.6% in the >50% CII group, respectively. A CII >25% was critical for determining DR progression (p < 0.001). CONCLUSIONS: Distortion created by UWFA needs to be corrected because the difference between UII and CII in DR increases with the ischemic index.
Adult ; Aged ; Aged, 80 and over ; Diabetic Retinopathy/*diagnosis/pathology ; Female ; Fluorescein Angiography/*methods ; Humans ; Ischemia/pathology ; Male ; Middle Aged ; Retinal Vein/pathology ; Retrospective Studies ; Sensitivity and Specificity

PURPOSE: To determine if short term effects of intravitreal anti-vascular endothelial growth factor or steroid injection are correlated with fluid turbidity, as detected by spectral domain optical coherence tomography (SD-OCT) in diabetic macular edema (DME) patients. METHODS: A total of 583 medical records were reviewed and 104 cases were enrolled. Sixty eyes received a single intravitreal bevacizumab injection (IVB) on the first attack of DME and 44 eyes received triamcinolone acetonide treatment (IVTA). Intraretinal fluid turbidity in DME patients was estimated with initialintravitreal SD-OCT and analyzed with color histograms from a Photoshop program. Central macular thickness and visual acuity using a logarithm from the minimum angle of resolution chart, were assessed at the initial period and 2 months after injections. RESULTS: Visual acuity and central macular thickness improved after injections in both groups. In the IVB group, visual acuity and central macular thickness changed less as the intraretinal fluid became more turbid. In the IVTA group, visual acuity underwent less change while central macular thickness had a greater reduction (r = -0.675, p = 0.001) as the intraretinal fluid was more turbid. CONCLUSIONS: IVB and IVTA injections were effective in reducing central macular thickness and improving visual acuity in DME patients. Further, fluid turbidity, which was detected by SD-OCT may be one of the indexes that highlight the influence of the steroid-dependent pathogenetic mechanism.
Aged ; Angiogenesis Inhibitors/*therapeutic use ; Bevacizumab/*therapeutic use ; Diabetic Retinopathy/*drug therapy/physiopathology ; Female ; Glucocorticoids/*therapeutic use ; Humans ; Intravitreal Injections ; Macular Edema/*drug therapy/physiopathology ; Male ; Middle Aged ; Nephelometry and Turbidimetry ; Retina/pathology ; *Subretinal Fluid ; Tomography, Optical Coherence ; Treatment Outcome ; Triamcinolone Acetonide/*therapeutic use ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology